Achieve Life Sciences, Inc.
ACHV
Rank in Stocks
#10423
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm,... Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Share Price
$6.78
Last synced: 2026-11-09
Market Cap
$697.68M
Change (1 day)
0.89%
Change (1 year)
42.14%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Achieve Life Sciences, Inc. (ACHV)
Category
Healthcare
EPS for Achieve Life Sciences, Inc. (ACHV)
EPS as of June 2026 TTM: $-1.55
According to Achieve Life Sciences, Inc.'s latest financial reports, its current EPS (TTM) is $-1.55. At the end of 2025 the company had an EPS of $-1.25, a decrease compared to its 2024 EPS of $-1.24.
EPS history for Achieve Life Sciences, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.55 | 24.00% |
| 2025 | $-1.25 | 0.81% |
| 2024 | $-1.24 | -17.33% |
| 2023 | $-1.50 | -62.03% |
| 2022 | $-3.95 | -2.47% |
| 2021 | $-4.05 | -24.86% |
| 2020 | $-5.39 | -86.23% |
| 2019 | $-39.15 | -45.84% |
| 2018 | $-72.29 | -83.63% |
| 2017 | $-441.47 | -70.14% |
| 2016 | $-1.48K | 4.60% |
| 2015 | $-1.41K | -55.68% |
| 2014 | $-3.19K | -33.16% |
| 2013 | $-4.77K | 39.01% |
| 2012 | $-3.43K | 3.45% |
| 2011 | $-3.32K | -15.75% |
| 2010 | $-3.94K | -306.71% |
| 2009 | $1.91K | -213.58% |
| 2008 | $-1.68K | -87.99% |
| 2007 | $-13.97K | -44.83% |
| 2006 | $-25.32K | -7.45% |
| 2005 | $-27.36K | -9.58% |
| 2004 | $-30.26K | 30.96% |
| 2003 | $-23.11K | -31.49% |
| 2002 | $-33.73K | -1,928.87% |
| 2001 | $1.84K | -120.78% |
| 2000 | $-8.87K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,110.32% |
US
|
|
| $-7.07 | 356.13% |
US
|
|
| $-5.29 | 241.29% |
AU
|
|
| $12.88 | -930.97% |
BE
|
|
| $21.56 | -1,490.97% |
NL
|
Questions about Achieve Life Sciences, Inc.'s earnings per share (EPS)
What is Achieve Life Sciences, Inc.'s earnings per share (EPS)?
Achieve Life Sciences, Inc.'s earnings per share (EPS) over the last twelve months is $-1.55, as of Jun 2026.
What was Achieve Life Sciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Achieve Life Sciences, Inc.'s earnings per share (EPS) was $-1.25, compared with $-1.24 in 2024.
How has Achieve Life Sciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Achieve Life Sciences, Inc.'s earnings per share (EPS) was highest in 2024 ($-1.24) and lowest in 2020 ($-5.39).
How does Achieve Life Sciences, Inc.'s earnings per share (EPS) compare with similar companies?
Achieve Life Sciences, Inc.'s earnings per share (EPS) ($-1.55) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.